Esperion Therapeutics (ESPR) Shares are Down -2.03%

Esperion Therapeutics (ESPR) : During the past 4 weeks, traders have been relatively bearish on Esperion Therapeutics (ESPR), hence the stock is down -1.91% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -1.38% relative to the S&P 500. The 4-week change in the price of the stock is -2.12% and the stock has fallen -2.03% in the past 1 week.

Company shares have received an average consensus rating of Hold for the current week The stock has recorded a twenty day Moving Average of 2.76% and the fifty day Moving Average is 10.26%. Esperion Therapeutics, Inc. has dropped 35.02% during the last three month period . Year-to-Date the stock performance stands at -52.25%.

Esperion Therapeutics (ESPR) : Currently there are 9 street experts covering Esperion Therapeutics (ESPR) stock. The most bullish and bearish price target for the stock is $64 and $11 respectively for the short term. The average price target of all the analysts comes to $24.17. The estimated standard deviation from the target is $17.01.


Esperion Therapeutics (NASDAQ:ESPR): stock turned positive on Friday. Though the stock opened at $10.58, the bulls momentum made the stock top out at $10.75 level for the day. The stock recorded a low of $10.31 and closed the trading day at $10.63, in the green by 1.24%. The total traded volume for the day was 251,462. The stock had closed at $10.5 in the previous days trading.

Esperion Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of patients with hypercholesterolemia and other cardio-metabolic risk markers. The Companys primary activities include conducting research and development activities, including nonclinical, preclinical and clinical testing, performing business and financial planning, recruiting personnel, and raising capital. ETC-1002, the Companys lead product candidate, is an orally available, once-daily small molecule designed to lower LDL-cholesterol levels and avoid the side effects associated with other LDL-cholesterol lowering therapies currently available. ETC-1002 is being developed for patients with hypercholesterolemia. One completed Phase IIb clinical study and a second that is nearing completion build upon a Phase I and Phase II clinical development program for ETC-1002.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.